One of the benefits resulting from the wave of cannabis legalization that is sweeping across North America and other parts of the world, is the increased acceptance, recognition, and acknowledgement by prominent physicians and researchers that there may be viable therapeutic potential for cannabinoids, including THC and also cannabidiol (“CBD”). This has led to a wide variety of preclinical and clinical studies to examine the therapeutic benefits of cannabis. Vitality Biopharma Inc (OTCMKTS:VBIO) is an example of such a company.
Vitality Biopharma is developing proprietary cannabinoid pharmaceuticals for treatment of serious neurological and inflammatory disorders. Vitality’s targeted prodrug technology enables delivery of cannabinoids to the site of disease while reducing or eliminating psychoactivity. Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.